Efficacy and safety of methotrexate in the management of inflammatory bowel disease: A systematic review and meta-analysis of randomized, controlled trials.
Crohn's disease
Inflammatory bowel disease
Methotrexate
Therapy
Ulcerative colitis
Journal
EClinicalMedicine
ISSN: 2589-5370
Titre abrégé: EClinicalMedicine
Pays: England
ID NLM: 101733727
Informations de publication
Date de publication:
Mar 2020
Mar 2020
Historique:
received:
20
08
2019
revised:
16
01
2020
accepted:
16
01
2020
entrez:
18
4
2020
pubmed:
18
4
2020
medline:
18
4
2020
Statut:
epublish
Résumé
The therapeutic role of methotrexate (MTX) for management of inflammatory bowel disease (IBD) remains unclear. We systematically reviewed randomized, controlled trials (RCTs) of MTX for induction and maintenance of remission in IBD until January 2020 in accordance with PROSPERO protocol (#CRD42018115047). Relative risk (RR) of maintenance of remission, induction of remission, endoscopic disease activity, and adverse events were combined in a meta-analysis. MTX monotherapy was not superior to placebo for induction of clinical remission in Crohn's disease (CD). However, MTX was superior to placebo in maintaining clinical remission of CD. Concomitant therapy with MTX and the TNF inhibitor infliximab (IFX) was not superior to IFX monotherapy in CD. In ulcerative colitis (UC), MTX monotherapy was not superior to placebo neither for induction of clinical remission, nor for maintenance of clinical remission. MTX did not result in superior endoscopic outcomes during induction or maintenance therapy compared with placebo. Regarding adverse events (AEs), our meta-analysis on CD studies showed a significantly higher risk of AEs when comparing MTX versus placebo in studies investigating induction of remission, but not in maintenance of remission. In UC, no such differences in AEs between MTX or placebo were observed. Current data support the efficacy of parenteral MTX monotherapy for maintenance of clinical remission in CD. MTX is not confirmed to be effective for treatment of UC or for induction of remission in CD. No evidence supports concomitant MTX to improve efficacy of IFX (no other biologics investigated).
Sections du résumé
BACKGROUND
BACKGROUND
The therapeutic role of methotrexate (MTX) for management of inflammatory bowel disease (IBD) remains unclear.
METHODS
METHODS
We systematically reviewed randomized, controlled trials (RCTs) of MTX for induction and maintenance of remission in IBD until January 2020 in accordance with PROSPERO protocol (#CRD42018115047). Relative risk (RR) of maintenance of remission, induction of remission, endoscopic disease activity, and adverse events were combined in a meta-analysis.
FINDINGS
RESULTS
MTX monotherapy was not superior to placebo for induction of clinical remission in Crohn's disease (CD). However, MTX was superior to placebo in maintaining clinical remission of CD. Concomitant therapy with MTX and the TNF inhibitor infliximab (IFX) was not superior to IFX monotherapy in CD. In ulcerative colitis (UC), MTX monotherapy was not superior to placebo neither for induction of clinical remission, nor for maintenance of clinical remission. MTX did not result in superior endoscopic outcomes during induction or maintenance therapy compared with placebo. Regarding adverse events (AEs), our meta-analysis on CD studies showed a significantly higher risk of AEs when comparing MTX versus placebo in studies investigating induction of remission, but not in maintenance of remission. In UC, no such differences in AEs between MTX or placebo were observed.
INTERPRETATION
CONCLUSIONS
Current data support the efficacy of parenteral MTX monotherapy for maintenance of clinical remission in CD. MTX is not confirmed to be effective for treatment of UC or for induction of remission in CD. No evidence supports concomitant MTX to improve efficacy of IFX (no other biologics investigated).
Identifiants
pubmed: 32300735
doi: 10.1016/j.eclinm.2020.100271
pii: S2589-5370(20)30015-8
pii: 100271
pmc: PMC7152823
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100271Informations de copyright
© 2020 Published by Elsevier Ltd.
Déclaration de conflit d'intérêts
The authors have no competing interests to declare as concerns MTX. In general, OHN, CS, CBJ have no conflicts of interest to disclose. Gerhard Rogler has consulted to Abbvie, Augurix, BMS, Boehringer, Calypso, Celgene, FALK, Ferring, Fisher, Genentech, Gilead, Janssen, MSD, Novartis, Pfizer, Phadia, Roche, UCB, Takeda, Tillots, Vifor, Vital Solutions and Zeller; received speaker's honoraria from Astra Zeneca, Abbvie, FALK, Janssen, MSD, Pfizer, Phadia, Takeda, Tillots, UCB, Vifor and Zeller; and educational grants and research grants from Abbvie, Ardeypharm, Augurix, Calypso, FALK, Flamentera, MSD, Novartis, Pfizer, Roche, Takeda, Tillots, UCB and Zeller.
Références
Stat Med. 2000 Nov 30;19(22):3127-31
pubmed: 11113947
Clin Pharmacokinet. 2016 Mar;55(3):257-74
pubmed: 26255287
Lancet. 2018 Dec 23;390(10114):2779-2789
pubmed: 29096949
J Crohns Colitis. 2017 Jul 1;11(7):769-784
pubmed: 28513805
Dig Dis Sci. 2019 Jun;64(6):1622-1631
pubmed: 30560332
Inflamm Bowel Dis. 2016 Jan;22(1):224-33
pubmed: 26457382
Gastroenterology. 2014 Mar;146(3):681-688.e1
pubmed: 24269926
Aliment Pharmacol Ther. 1996 Jun;10(3):309-14
pubmed: 8791956
Am J Gastroenterol. 2010 Mar;105(3):501-23; quiz 524
pubmed: 20068560
Gastroenterology. 2018 Oct;155(4):1098-1108.e9
pubmed: 29964043
Gut. 1989 Jul;30(7):983-9
pubmed: 2668130
Gastroenterology. 2003 Nov;125(5):1508-30
pubmed: 14598268
Eur J Gastroenterol Hepatol. 2004 Sep;16(9):921-6
pubmed: 15316419
Ann Intern Med. 1977 Feb;86(2):199-204
pubmed: 319725
Cochrane Database Syst Rev. 2014 Jun 10;(6):CD000957
pubmed: 24916606
J Clin Pharmacol. 2013 Jun;53(6):575-88
pubmed: 23408468
Eur J Gastroenterol Hepatol. 2000 Nov;12(11):1227-33
pubmed: 11111780
Gastroenterology. 1976 Mar;70(3):439-44
pubmed: 1248701
Eur J Gastroenterol Hepatol. 2012 Sep;24(9):1086-91
pubmed: 22713509
Clin Gastroenterol Hepatol. 2013 Jun;11(6):667-72
pubmed: 23333660
Inflamm Bowel Dis. 2015 Aug;21(8):1982-92
pubmed: 26154136
Dig Dis Sci. 1993 Oct;38(10):1851-6
pubmed: 8404406
Lancet Gastroenterol Hepatol. 2019 May;4(5):341-353
pubmed: 30824404
Gastrointest Endosc. 2004 Oct;60(4):505-12
pubmed: 15472670
Gut. 1998 Jul;43(1):29-32
pubmed: 9771402
Aliment Pharmacol Ther. 2011 Mar;33(6):714-21
pubmed: 21235604
Aliment Pharmacol Ther. 2003 Nov 15;18(10):1003-8
pubmed: 14616166
J Crohns Colitis. 2017 Jan;11(1):3-25
pubmed: 27660341
Ann Med. 2010 Mar;42(2):97-114
pubmed: 20166813
Inflamm Bowel Dis. 2013 Jun;19(7):1379-83
pubmed: 23542534
Dig Liver Dis. 2003 Sep;35(9):619-27
pubmed: 14563183
Nat Rev Rheumatol. 2010 Mar;6(3):175-8
pubmed: 20197777
N Engl J Med. 1995 Feb 2;332(5):292-7
pubmed: 7816064
Am J Gastroenterol. 1997 Dec;92(12):2203-9
pubmed: 9399753
Am J Gastroenterol. 2015 Sep;110(9):1324-38
pubmed: 26303131
Inflamm Bowel Dis. 2010 Mar;16(3):377-8
pubmed: 19575354
Gastroenterology. 1996 May;110(5):1416-21
pubmed: 8613046
Lancet. 1980 Mar 8;1(8167):514
pubmed: 6102236
Ann Intern Med. 1989 Mar 1;110(5):353-6
pubmed: 2492786
Aliment Pharmacol Ther. 2012 Jan;35(2):284-91
pubmed: 22112005
Inflamm Bowel Dis. 2018 Feb 15;24(3):539-545
pubmed: 29462391
Aliment Pharmacol Ther. 2002 Oct;16(10):1751-9
pubmed: 12269968
Digestion. 2017 Oct 24;96(4):220-227
pubmed: 29065423
Gut. 2010 Oct;59(10):1363-8
pubmed: 20587545
Ann Intern Med. 2018 Dec 11;170(2):129-130
pubmed: 30535358
J Crohns Colitis. 2019 Aug 14;13(8):990-995
pubmed: 30888405
Clin Transl Gastroenterol. 2017 Jul 13;8(7):e106
pubmed: 28703786
Clin Gastroenterol Hepatol. 2019 Oct;17(11):2262-2268
pubmed: 30853615
N Engl J Med. 2000 Jun 1;342(22):1627-32
pubmed: 10833208
Aliment Pharmacol Ther. 2017 Jan;45(2):276-282
pubmed: 27862102
Inflamm Bowel Dis. 2010 Jul;16(7):1195-202
pubmed: 19924799
JAMA. 2017 Nov 7;318(17):1679-1686
pubmed: 29114832
Eur J Gastroenterol Hepatol. 2006 Jan;18(1):11-6
pubmed: 16357613
J Crohns Colitis. 2017 Mar 1;11(suppl_2):S576-S585
pubmed: 27797917
Gastroenterology. 2015 Jan;148(1):37-51.e1
pubmed: 25127678
Am J Gastroenterol. 2000 Jul;95(7):1730-4
pubmed: 10925976
Inflamm Bowel Dis. 2016 Aug;22(8):1887-95
pubmed: 27057681
Clin Gastroenterol Hepatol. 2018 May;16(5):624-626
pubmed: 29409805
J Gastroenterol Hepatol. 2008 Jun;23(6):954-8
pubmed: 17559377
Pharmacol Ther. 2018 Dec;192:100-111
pubmed: 30048708
Aliment Pharmacol Ther. 2001 Jan;15(1):35-44
pubmed: 11136276
Trends Pharmacol Sci. 2017 Feb;38(2):127-142
pubmed: 27916280
N Engl J Med. 2013 Aug 22;369(8):754-62
pubmed: 23964937
J Clin Gastroenterol. 2008 Apr;42(4):395-9
pubmed: 18277899
Clin Gastroenterol Hepatol. 2019 Aug;17(9):1680-1713
pubmed: 30853616
Ann Rheum Dis. 2018 Oct;77(10):1463-1470
pubmed: 29936438
N Engl J Med. 1987 Dec 24;317(26):1625-9
pubmed: 3317057
Clin Gastroenterol Hepatol. 2013 Apr;11(4):444-7
pubmed: 23103905
Gastroenterology. 2016 Feb;150(2):380-8.e4
pubmed: 26632520
Aliment Pharmacol Ther. 2009 Sep 15;30(6):614-20
pubmed: 19552632
Aliment Pharmacol Ther. 2017 Apr;45(8):1128-1134
pubmed: 28230306
Hepatogastroenterology. 1999 May-Jun;46(27):1724-9
pubmed: 10430331
Gut. 2007 Sep;56(9):1226-31
pubmed: 17229796
Gastroenterology. 2013 Dec;145(6):1464-78.e1-5
pubmed: 24267475
Am J Gastroenterol. 2018 Apr;113(4):481-517
pubmed: 29610508